CGA
AZN icon

Crescent Grove Advisors’s AstraZeneca AZN Stock Holding History

Crescent Grove Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,593
Closed -$302K – 294
2021
Q4 		$302K Hold
2,593
– – 0.03% 234
2021
Q3 		$311K Buy
+2,593
New +$302K 0.03% 198

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Crescent Grove Advisors's AZN Position: Q1 2022 in Review

Crescent Grove Advisors sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 2,593 shares — an estimated $302K sold.

Crescent Grove Advisors first reported a position in AZN in Q3 2021 and held it in 2 quarters. The position peaked at $311K in Q3 2021. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

  • Crescent Grove Advisors reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
  • Crescent Grove Advisors sold 2,593 AstraZeneca shares in Q1 2022, an estimated $302K.
  • Crescent Grove Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 2 quarters.
  • Crescent Grove Advisors's AstraZeneca position peaked at $311K in Q3 2021.
  • 982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Crescent Grove Advisors's 13F filing for Q1 2022, filed 4 May 2022.